Abstracts Archive - Page 122 of 2607 - ACR Meeting Abstracts

Abstract Number: 1657 • ACR Convergence 2025
Extracting TNF Inhibitor Switching Reasons and Trajectories From Real-World Data Using Large Language Models
Brenda Miao¹, Marie Binvignat², Augusto Garcia-Agundez³, Maxim Bravo⁴, Christopher Williams⁵, Claire Miao⁴, Ahmed Alaa⁶, Vivek Rudrapatna⁵, gabriela Schmajuk⁷ and Jinoos Yazdany³, ¹UCSF, Fremont, CA, ²Sorbonne University, Paris, France, ³UCSF, San Francisco, CA, ⁴UC Berkeley, San Francisco, ⁵UCSF, San Francisco, ⁶UC Berkeley, Berkeley, ⁷University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are cornerstones of autoimmune‑disease therapy, yet many patients switch agents because of loss of effectiveness, adverse events, or insurance…
Abstract Number: 1542 • ACR Convergence 2025
Alternative Definitions of Moderate Flares That Simulate Clinical Practice in Systemic Lupus Erythematosus: Post Hoc Exploration of Moderate Flares in Patients Treated with Dapirolizumab Pegol in a 48-Week Phase 3 Trial
Richard Furie¹, George Bertsias², Lucy Carter³, Eric Morand⁴, Marta Mosca⁵, Marilyn Pike⁶, Vanessa Taieb⁷, Annette Nelde⁸, Ed Vital⁹ and Christian Stach¹⁰, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁵University of Pisa, Pisa, Pisa, Italy, ⁶Rheumatology, MedPharm Consulting, Inc., Bethesda, MD, ⁷UCB, Colombes, France, ⁸Biogen, Baar, Switzerland, ⁹University of Leeds, Leeds, England, United Kingdom, ¹⁰UCB, Monheim am Rhein, Germany
Background/Purpose: Despite the evolution of various flare definitions and their inclusion in SLE clinical trials, moderate flares tend to be underestimated in trials owing to…
Abstract Number: 1598 • ACR Convergence 2025
Use of JAK Inhibitors in Medium- and Small-Sized Vasculitides: a Retrospective Multicenter Study
caterina ricordi¹, elena treppo², Pavel Novikov³, Paul Russo⁴, Luca moroni⁵, Angelo Fassio⁶, Paolo Delvino⁷, hervé lobbes⁸, Chiara Marvisi¹, Francesco Muratore¹, Xavier Puéchal⁹, Carlo Salvarani¹ and Benjamin Terrier¹⁰, ¹Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ²Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ³Sechenov University, Moscow, Russia, ⁴Royal Adelaide Hospital, Clinical Immunology and Allergy, Adelaide, Australia, ⁵IRCCS San Raffaele, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milan, Italy, ⁶University of Verona, Department of Medicine, Unit of Rheumatology, Verona, Italy, ⁷University of Milano-Bicocca, Monza, Monza and Brianza, Italy, ⁸Department of Internal Medicine, Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France, ⁹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ¹⁰Cochin Hospital, Paris, France
Background/Purpose: Medium- and small-vessel vasculitides (MVV and SVV) are a heterogeneous group of inflammatory diseases affecting the vascular wall. Current treatment strategies are based on…
Abstract Number: 1608 • ACR Convergence 2025
Efficacy of Anti-IL-5/R Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis
Peter Merkel¹, Arnaud Bourdin², Bernhard Hellmich³, Nader Khalidi⁴, David Jackson⁵, David Jayne⁶, Parameswaran Nair⁷, Christian Pagnoux⁸, Ulrich Specks⁹, Benjamin Terrier¹⁰, Lena Börjesson Sjö¹¹, Priya Jain¹², Aadarsh Lal¹³, Sofia Necander¹⁴, Claire Walton¹⁵ and Michael Wechsler¹⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁸Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ⁹Mayo Clinic, Rochester, MN, ¹⁰Cochin Hospital, Paris, France, ¹¹Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ¹²BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹³Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ¹⁴Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁵Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁶Department of Medicine, National Jewish Health, Denver
Background/Purpose: Results from the 1-year double-blind period and first year of the open-label extension (OLE) of the MANDARA trial (NCT04157348) demonstrated that over 60% of…
Abstract Number: 1640 • ACR Convergence 2025
Physical Function and Performance in SLE: A Comparison of Two Population-Based Cohorts
Jessica Fitzpatrick¹, Mrinalini Dey², C. Barrett Bowling³, S. Sam Lim⁴, Courtney Hoge⁵, Charmayne Dunlop-Thomas⁵, Maria Dall'Era⁶, Patti Katz⁷, Jinoos Yazdany¹ and Laura Plantinga⁸, ¹UCSF, San Francisco, CA, ²Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ³Duke University, Durham, NC, ⁴Emory University School of Medicine, Atlanta, GA, ⁵Emory University, Atlanta, GA, ⁶Division of Rheumatology, University of California, San Francisco, CA, ⁷UCSF, San Rafael, CA, ⁸University of California, San Francisco, San Francisco, CA
Background/Purpose: Physical function and performance are top priorities to individuals with systemic lupus erythematosus (SLE). Suboptimal physical function and performance are associated with disability, loss…
Abstract Number: 1512 • ACR Convergence 2025
Anti-U1-RNP Antibody Positivity is Associated with Elevated Interferon Score in SLE Irrespective of Disease Activity: A Transcriptome Analysis in Japanese Patients
Takemichi Matsui¹, Yumi Tsuchida², Takahiro Itamiya², Mineto Ota², Toshihiko Komai², Haruka Tsuchiya², Hirofumi Shoda², Tomohisa Okamura² and Keishi Fujio², ¹Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: With the introduction of anifrolumab to clinical practice, there is a growing interest in identifying factors associated with IFN activity in patients with SLE.…
Abstract Number: 1663 • ACR Convergence 2025
Tocilizumab for acute exacerbation of rheumatic disease-related interstitial lung disease: A prospective real-world study
Wenwen Xu¹, Yiyangzi Ma², Shuang Ye³ and Qiong Fu², ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China (People's Republic), ³Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Acute exacerbation (AE) of rheumatic disease-related interstitial lung disease (RD-ILD) is a severe and potentially life-threatening condition, while there remains no clear consensus of…
Abstract Number: 1649 • ACR Convergence 2025
Does Physical Activity Differ Among those with Autoimmune vs Non-Autoimmune Rheumatic Diseases?
Sydney Liles¹, Jennifer Copson², Yvonne Lee³ and Daniel K. White¹, ¹University of Delaware, Newark, DE, ²University of Delaware, Wilmington, DE, ³Northwestern University, Chicago, IL
Background/Purpose: Individuals with rheumatic conditions, such as Rheumatoid Arthritis (RA) and Osteoarthritis (OA), often experience low physical activity levels. Physical activity may vary by autoimmune…
Abstract Number: 1509 • ACR Convergence 2025
Outcome of Newly Diagnosed SLE with Serositis and Its Clinical Features in Daily Clinical Practice: A Single Center Study
Shuzo Sato, Kaito Moriuchi, So Yamamoto, Hiroki Nibu, Takahito Sakamoto, Shotaro Ogawa, Kenji Saito, Yuya Sumichika, Shuhei Yoshida, Haruki Matsumoto, Jumpei Temmoku and Tomoyuki Asano, Fukushima Medical University, Fukushima, Fukushima, Japan
Background/Purpose: Past reports have shown that serositis is a risk factor for organ damage in patients with SLE. However, the distinct clinical features of newly…
Abstract Number: 1669 • ACR Convergence 2025
Development and Validation of Minimal Disease Activity and Disease Flare for Children with Chronic Nonbacterial Osteomyelitis Using a Consensus and Data-Driven Approach
Farzana Nuruzzaman¹, Natalie Rossenwasser², Xing Wang³, Ava Klein³, Ian Muse⁴, Erin Balay-Dustrude⁵, Megan Nguyen⁶, Emily Deng³, Jonathan Akikusa⁷, Matthew Basiaga⁸, Lindsey Bergstrom⁹, Fatma Dedeoglu¹⁰, Bin Huang¹¹, Jenna King¹², Sivia Lapidus¹³, Tzielan Lee¹⁴, Aleksander Lenert¹⁵, Cassandra Levesque¹⁶, Lillian Lim¹⁷, Kimberly Martin¹⁸, Elizabeth Murray¹⁹, Melissa Oliver²⁰, Karen Onel²¹, Seza Özen²², Lauren Potts²³, Sara M. Stern²⁴, Robin Villaverda²⁵, Eveline Wu²⁶, Ronald laxer²⁷, Polly Ferguson²⁸, Daniel Lovell²⁹ and Yongdong (Dan) Zhao³⁰, ¹Stony Brook Children's Hospital, Stony Brook, NY, ²Seattle Children's Hospital, Seattle, WA, ³Seattle Children's Hospital, Seattle, ⁴University of Washington, Department of Pediatrics, Seattle Children's Hospital, Seattle, ⁵University of Washington, Seattle, WA, ⁶Seattle Children’s Research Institute, Seattle, ⁷The Royal Children's Hospital, Parkville, Victoria, Australia, ⁸Mayo Clinic, Rochester, MN, ⁹Patient/parent research partner, Harpswell, ME, ¹⁰Boston Children's Hospital, Boston, MA, ¹¹Cincinnati Children's Hospital, Cinciannati, OH, ¹²Patient/parent Research Partner, Planation, FL, ¹³Joseph M. Sanzari Children's Hospital, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Montclair, NJ, ¹⁴Stanford University School of Medicine, Palo Alto, CA, ¹⁵Iowa Carver College of Medicine, Iowa City, IA, ¹⁶Patient/parent research partners, DC district, DC, ¹⁷University of Alberta, Edmonton, AB, Canada, ¹⁸Patient/parent research partners, Houston, TX, ¹⁹Patient/parent research partners, Lynnwood, WA, ²⁰Indiana University, Indianapolis, IN, ²¹HSS, New York, NY, ²²Hacettepe University Medical Faculty, Ankara, Turkey, ²³Patient/parent research partners, Santa Cruiz, CA, ²⁴University of Utah, Salt Lake City, UT, ²⁵Patient/parent research partners, Thorton, CO, ²⁶UNC Chapel Hill, Chapel Hill, NC, ²⁷The Hospital for Sick Children, Toronto, ON, Canada, ²⁸University of Iowa Carver College of Medicine, Iowa City, IA, ²⁹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³⁰Seattle Children’s Research Institute, Redmond, WA
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an inflammatory bone disease that can result in bone destruction/deformity, persistent bone pain and pathological fractures. Due to the…
Abstract Number: 1522 • ACR Convergence 2025
Outcomes of Continuing Hydroxychloroquine following Renal Transplant in Patients with Lupus Nephritis: A retrospective Cohort Study using the TrinetX database
Carlos Pena¹, Irene Tan², Rafal Ali³, Arthur Lau⁴, Shahrzad Abdollahi⁵, Fabian Rodriguez Quinonez⁶ and Marianne Meshreky⁷, ¹Jefferson Einstein Philadelphia, Wynnewood, PA, ²Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA, ³Jefferson Einstein Philadelphia, Lansdale, PA, ⁴Jefferson Einstein Hospital, Maple Glen, PA, ⁵Jefferson Einstein Hospital, Philadelphia, PA, ⁶Einstein Medical Center Philadelphia, Philadelphia, PA, ⁷St. Mary's Hospital, Philadelphia
Background/Purpose: Evidence of kidney disease occurs in up to one half of patients with SLE, and approximately 10% of the patients with lupus nephritis (LN)…
Abstract Number: 1636 • ACR Convergence 2025
The Impact of Arthritis on Self-Management Activities of West Virginia Adults with Type 2 Diabetes During the COVID-19 Pandemic
Dina Maruca¹, Teresa Brady², Gerald Hobbs, Jr.¹ and Ranjita Misra¹, ¹West Virginia University, Morgantown, WV, ²Clarity Consulting and Communications, Atlanta, GA
Background/Purpose: One-third of adults with Type 2 diabetes (T2D) also have arthritis. West Virginia (WV), the 3rd most rural US state, has the highest prevalence…
Abstract Number: 1536 • ACR Convergence 2025
Evaluating Systemic Lupus Erythematosus Remission Among Patients Initiating Belimumab in a Real-World Setting in the USA
Aarat M Patel¹, Renee L. Gennarelli², Temitope Bello², Ali Bonakdar² and Karen Worley³, ¹GSK, US Medical Affairs, Durham, NC, ²Cencora, Real-World Evidence, Conshohocken, PA, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA
Background/Purpose: The Definition Of Remission In SLE (DORIS) criteria were developed to provide alignment on defining remission in patients with SLE.1,2 Belimumab (BEL) treatment increases…
Abstract Number: 1661 • ACR Convergence 2025
Artificial Intelligence applied to Patient Reported Outcomes and Passive Physiologic Sensor Data can Accurately Classify Low Disease Activity in Rheumatoid Arthritis Patients
Jeffrey Curtis¹, Yujie Su², sam Barskiy³, Emily Holladay³, Shilpa Venkatachalam⁴, David Curtis⁵, Tapan Mehta³ and Fenglong Xie⁶, ¹Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Global Healthy Living Foundation, New York, NY, ⁵Global Healthy Living Foundation, Meriden, ⁶The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Remote therapeutic monitoring (RTM) and remote physiologic monitoring (RPM) programs have the potential to capture data between clinical visits and provide information back to…
Abstract Number: 1612 • ACR Convergence 2025
Window of opportunity with tocilizumab therapy in giant cell arteritis. Multicenter study of 471 patients of clinical practice
Adrian Martin-Gutierrez¹, Javier Loricera², Diana Prieto-Peña³, Vicente Aldasoro Cáceres⁴, Olga Maiz⁵, Eugenio de Miguel⁶, Eva Galíndez Agirregoikoa⁷, Ivan Ferraz Amaro⁸, Santos Castañeda⁹ and Ricardo Blanco¹⁰, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁴Hospital Universitario de Navarra, Pamplona, Spain, ⁵Hospital Universitario de Donosti, Donostia, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁸Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Tocilizumab (TCZ) is the only biological drug currently approved for the treatment of giant cell arteritis (GCA), regardless of GCA duration. The “window of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].